DEA proposes Schedule I status for five tryptamines as Oregon drops psilocybin fee hikes and GAO questions scheduling procedures

Federal and state psychedelic policy shifted across three major developments. The DEA proposed placing five tryptamines - 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT - in Schedule I, a move that could add registration requirements for researchers and affect commercial development, including a postpartum depression drug candidate based on a 4-OH-DiPT prodrug. In Oregon, the Health Authority withdrew proposed rules that would have doubled psilocybin license fees after public opposition, but it has not explained how to address a projected $3.8 million biennial shortfall. A new GAO audit found that DEA followed HHS recommendations in all 84 finalized scheduling decisions examined from 2020 through 2025, while both agencies lacked comprehensive written procedures for evaluating substances and weighing factors such as abuse potential. The findings highlight uncertainty for psychedelic research, drug approvals, and future rescheduling efforts.